How do you incorporate genomic classifier results into treatment decisions for patients with very high-risk nonmetastatic prostate cancer receiving radiation and long-term ADT?
Howlett et al., ESMO 2026 (Abstract 2045O). In STAMPEDE, a higher Decipher score predicted greater abiraterone benefit for MFS but not OS. Would a low score lead you to omit abiraterone, and does a high score change how you counsel patients about intensification?
Community PollStarted
Would you omit abiraterone for STAMPEDE-eligible very high risk prostate ca with a low Decipher score?
245 physicians have voted
Join Mednetto vote and see how they answered.